

IMI 10th Anniversary Scientific Symposium

Draft Agenda Day 1 22.10.18

22.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00 Registration & welcome coffee

09:00 – 10:00 Opening session

Pierre Meulien, Executive Director, IMI
Jean-Christophe Tellier, Chief Executive Officer and Chairman of the Executive Committee, UCB
Jonathan Knowles, Professor, Founding Chairman of IMI Board

10:00 – 11:00 Stratification towards personalised medicines

10:00 – 10:15 Setting the scene

- Pierre Meulien, Executive Director, IMI

10:15 – 11:00 Presentation of key achievements from IMI projects

- “Using Multi-Scale Genetic, Neuroimaging and Clinical Data for Predicting Alzheimer’s Disease and Reconstruction of Relevant Mechanisms”, AETIONOMY, Fröhlich Holger, UCB
- “Quantitative PET Imaging - From Research to Clinical Use”, AMYPAD, Heeman Fiona, VU University medical centre
- “Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: A showcase from the epidemiological studies within the IMI DIRECT Consortium”, DIRECT, Koivula Robert, University of Oxford

11:00 – 11:30 Coffee break

11:30 – 12:15 Presentation of key achievements from IMI projects

- “Predicting Cognitive Decline through Structural MRI biomarkers: Results from the EMIF-AD Biomarker Discovery Study”, EPAD, Ingala Silvia, VU Medical Center
- “The EU-AIMS Longitudinal European Autism Project: Examples of novel approaches to biomarker discovery”, EU-AIMS, Stefan Holiga, F. Hoffmann-La Roche & Loth Eva, King's College London
- “Biomarker methods to enable stratification of patient populations in clinical trials for neuropathic pain”, EUROPAIN, Vollert Jan, Imperial College London
- “Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors”, Onco Track, Risch Thomas, Max Planck Institute for Molecular Genetics and Schütte Moritz, Alacris Theranostics GmbH
- “Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression”, PRECISESADS, Toro Daniel, GENYO



12:15 – 13:30 Lunch

- 13:30 – 14:00 Presentation of key achievements from IMI projects
- “Federating clinical data for biomedical research in type 2 diabetes”, RHAPSODY, Sparsø Thomas, Novo Nordisk
 - “Building handprints of complex diseases – severe asthma as a proof of concept”, U-BIOPRED and eTRIKS, De Meulder Bertrand, European Institute for Systems Biology and Medicine
- 14:00 – 14:30 Panel discussion:
- Pamela Tenaerts, Executive Director, Clinical Trial Transformation Initiative
 - Raj Long, Senior Regulatory Officer for Integrated Development in Global Health, Bill & Melinda Gates Foundation
 - Isabelle Bekeredjian-Ding, Head of Department bei, Paul-Ehrlich-Institut
 - Martin Hofmann-Apitius, Head of the Department of Bioinformatics, Fraunhofer SCAI


14:30 – 15:00 Coffee break

15:00 – 17:15 Patient centric approaches in drug development

- 15:00 – 15:15 Setting the scene
- Virginie Hivert, Therapeutic Development Director, EURORDIS
- 15:15 – 16:45 Presentation of key achievements from IMI projects
- “Patient involvement in the IMI-APPROACH project: invaluable insights and key ingredients”, APPROACH, Hussaarts Leonie, Lygature & Jane Taylor
 - “Patient education is a prerequisite for meaningful patient engagement in the life cycle of medicines”, EUPATI, Bereczky Tamàs, Eupati
 - “Driving the use of Real World Evidence in healthcare decision making”, GETREAL, Makady Amr, Zorginstituut Nederland
 - “When to consider patient preference information along the medical product lifecycle? An overview of decision points and situations”, PREFER, Chiara Whichello and Eline van Overbeeke, KU Leuven
 - “From development to labelling claim”, PRO-active, Demeyer Heleen, Uz Gasthuisberg
 - “Baseline characteristics of participants of the SPRINTT randomised clinical trial”, SPRINTT, Riccardo Calvani, Università Cattolica del Sacro Cuore
- 16:45 – 17:15 Panel discussion:
- Virginie Hivert, Therapeutic Development Director, EURORDIS
 - Mary Baker, President, European Brain Council
 - Fernand Sauer, Member, Académie National de Pharmacie
 - Olivier Arnaud, Senior Director, European Research JDRF

17:15 – 19:15 Poster session

18:00 – 22:00 Networking cocktail



Draft Agenda Day 2 23.10.18

23.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

08:30 – 09:00 Registration & welcome coffee

09:00 – 09:15 Introduction

09:00 – 09:15 Pierre Meulien, Executive Director, IMI

09:15 – 11:15 Enablers for discovery and development of new drugs

09:15 – 09:30 Setting the scene

- High level speaker (to be confirmed)

09:30 – 11:15 Presentation of key achievements from IMI projects

- “An iPSC technology development collaboration – a critical component to enable ADAPTED”, ADAPTED, Peter Reinhardt, AbbVie & Benjamin Schmid, Bioneer
- “Exploring the potential of lipidoid-polymer hybrid nanoparticles to deliver oligonucleotides to intracellular pharmacological targets”, COMPACT, Thanki Kaushik, University of Copenhagen
- “Supporting stem cell research with modern data management technologies”, EBISC, Seltmann Stefanie, Charité Berlin
- “EMIF Catalogue – the bridge between data custodians and biomedical researchers”, EMIF, Trifan Alina, University of Aveiro
- “HARMONY Platform: using Big Data to fight blood cancers”, HARMONY, Abáigar-Alvarado María, Institute of Biomedical Research of Salamanca
- “Supersaturation as driving force for intestinal absorption resulting in an increased oral bioavailability: case example with posaconazole”, ORBITO, Bart Hens, KU Leuven
- “Remote Assessment of Disease and Relapse in Major Depressive Disorder (RADAR-MDD): Study protocol”, RADAR-CNS, Matcham Faith, King's College London

11:15 – 11:45 Coffee break

11:45 – 12:15 Panel discussion:

- Stefan Jaroch, Head External Innovation Technologies, Global External Innovation & Alliances bei, Bayer Pharma AG
- Magali Haas, CEO & President, Cohen Veterans Bioscience
- Heiko Zimmermann, Head of Institute, Fraunhofer-Institut für Biomedizinische Technik IBMT
- Hans-Georg Eichler, Senior medical officer, European Medicines Agency



12:15 – 13:30 Lunch

13:30 – 15:30 Collaborating to fight infections

13:30 – 13:45 Setting the scene

- Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline

13:45 – 15:00 Presentation of key achievements from IMI projects


- “EURECA - Substudy of infections due to carbapenem-resistant Enterobacteriaceae (CRE) along Europe. Inside COMBACTE network; global information for a global problem”, COMBACTE-CARE, Paniagua Maria, Hospital Universitario Virgen Macarena
- “A new European network for influenza vaccine effectiveness studies”, DRIVE, Turunen Topi, FISABIO
- “Field validation of novel diagnostic tools for Ebola virus detection in Sierra Leone”, EbolaMoDRAD, Colavita Francesca, INMI
- “Modelling the humoral immune response to Ebola vaccine”, EBOVAC1, Balelli Irene, Inserm
- “Highly potent heavy chain only antibodies protect against MERS-CoV infection”, ZAPI, Okba Nisreen, Erasmus Medical Center

15:00 – 15:30 Panel discussion:

- Rino Rappuoli, Chief Scientist & Head of External Research and Development, GlaxoSmithKline
- Raj Long, Senior Regulatory Officer for Integrated Development in Global Health, Bill & Melinda Gates Foundation
- Seamus O'Brien, R&D Director, Global Antibiotic Research and Development Partnership (GARDP)

15:30 – 16:00 Coffee break

16:00 – 17:00 Closing & Prize ceremony




Poster Session


22 & 23.10.2018 • Crowne Plaza Le Palace •
Rue Gineste 3 • 1210 Brussels • Belgium

New targets, tools and pathways


- 1- *“Support Translation Research with High Quality Data and Interactive Visual-analytics”*
eTRIKS, Rege Kavita, University of Luxembourg
- 2- *“Developing a robust evidence base on RSV disease and economic burden using a multi-disciplinary approach”*
RESCEU, Reeves Rachel, the University of Edinburgh
- 3- *“AMYPAD Diagnostic and Patient Management Study (AMYPAD-DPMS): rationale and study design”*
AMYPAD, Altomare Daniele, IRCCS Fatebenefratelli
- 4- *“Network-based modeling of APAP-induced hepatotoxicity using interactomics and transcriptomics data”*
TransQST, Guney Emre, GRIB - IMIM / UPF
- 5- *“The use of antigen-presenting cells for vaccine immunogenicity testing in vitro”*
VAC2VAC, Van den Biggelaar Robin, Utrecht University
- 6- *“Stroke risk, bleeding risk and anticoagulation patterns derived from unstructured text in hospital EHRs”*
Big data @ heart, Bean Daniel, King's College London & HDR UK
- 7- *“DPP6 as a new biomarker suitable for human islet in vivo imaging”*
INNODIA, Demine Stéphane, ULB Center for Diabetes Research
- 8- *“Identification of Stratified Social-Behavioural Markers in Neuropsychiatric Disorders by using smartphone technology”*
PRISM, Jongs Niels, Rijksuniversiteit Groningen
- 9- *“Drug Evaluation in Guinea Pig Model”*
PreDiCT TB, Lanni Faye, Public Health England
- 10- *“The APPROACH Consortium: a 2-year, European, cohort study to describe, validate, and predict phenotypes of knee osteoarthritis using clinical, imaging, and biochemical markers”*
APPROACH, Van Helvoort Eefje, University Medical Centre Utrecht
- 11- *“In vivo models of Drug-induced interstitial lung disease; tools to study and improve drug safety”*
TRISTAN, Mahmutovic Persson Irma, Lund University
- 12- *“RNA-sequencing of medulloblastoma patient-derived orthotopic xenograft models enables identification of both tumor and microenvironment specific biomarkers”*
ITCC-P4, Jäger Natalie, DKFZ and KiTZ, Heidelberg



- 13- *"Molecular characterization of patient-derived orthotopic xenograft models of paediatric brain tumours"*
ITCC-P4, Brabetz Sebastian, Hopp Children's Cancer Center at the NCT Heidelberg (KITZ)
- 14- *"Candidate genes and pathways from ADAPTED Stage I integrative analysis"*
ADAPTED, Madrid Márquez Laura, CAEBi Bioinformatica
- 15- *"Increased understanding of AD pathophysiology through novel cerebrospinal fluid markers: results from the EMIF-AD Multimodal Biomarker Discovery study"*
EMIF-AD, Bos Isabelle, Maastricht University
- 16- *"Data analytics and bioinformatics to successfully define asthma subphenotypes"*
U-BIOPRED, Pavlidis Stelios, Data Science Institute, Imperial College London
- 17- *"Collaborative capacity building: Creating new knowledge, new tools, new collaborative ties and educating young scientist"*
K4DD, Slidrecht Tale, Lygature
- 18- *"Developing a mechanism-based taxonomy of Alzheimer's and Parkinson's disease"*
AETIONOMY, Golriz Khatami Sepehr, Fraunhofer SCAI
- 19- *"Proteome analyses in colorectal carcinoma reveals major protein alterations upon cancer development and metastasis"*
OncoTrack, Azimi Alireza, Uppsala University
- 20- *"Human iPSC-derived cells: a powerful tool for neuropathic pain disease modelling"*
NGN-PET, Rutigliano Lucia, Axxam
- 21- *"A new way to monitor Multiple Sclerosis"*
RADAR-CNS, Martinis Matteo, San Raffaele Hospital
- 22- *"Discovery of the role of the ELOVL2/docosahexaenoic acid axis in the regulation of insulin secretion and survival of rodent and human pancreatic beta cells"*
IMIDIA, Bellini Lara, Université Paris Diderot
- 23- *"Glucagon and gastrointestinal hormones changes after Roux-en-Y gastric bypass: an IMI DIRECT study"*
DIRECT, Frau Francesca, Sanofi
- 24- *"Application and optimization of Monocyte Activation Test for testing Tick Borne Encephalitis virus vaccine pyrogenicity"*
VAC2VAC, EtnaMarilena Paola, istituto Superiore di Sanità
- 25- *"Development of Rift Valley fever virus neutralizing antibodies using bacterial superglues"*
ZAPI, Wichgers Schreur Paul, Wageningen Bioveterinary Research
- 26- *"Interim Pharmacokinetic Analysis from the EVADE Phase 2 Clinical Trial of MEDI3902, a Bispecific Monoclonal Antibody Against PcrV and Psl of Pseudomonas aeruginosa"*
COMBACTE-MAGNET, Hernandez Ana Catalina, Centre Hospitalier Universitaire de Limoges




- 27- *"Interim Pharmacokinetic Analysis from the SAATELLITE Phase 2 Clinical Trial of MEDI4893, an Extended Half-life Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin"* **COMBACTE-NET, Hernandez Ana Catalina, Centre Hospitalier Universitaire de Limoges**
- 28- *"Urinary metabolites as potential biomarkers of P. aeruginosa ventilator-associated pneumonia"*
RAPP-ID, 's Jongers Bart, University of Antwerp
- 29- *"Laboratory Analysis workflows within the ASPIRE-ICU study"*
COMBACTE-NET and COMBACTE-MAGNET, Timbermont Leen, University of Antwerp
- 30- *"New bio-informatic approach for the analysis of flow cytometry data"*
PRECISESADS, Le Lann Lucas, University of Brest
- 31- *"Zebrafish Proteinopathy Models for Target Validation"*
IMPRiND, Hubbard Jeffrey, Institut de Recherches Servier
- 32- *"New candidate genes in insulin target tissues: Elov12 as a protective enzyme against glycaemic deterioration?"*
RHAPSODY, Lallement Justine, Université Paris Diderot
- 33- *"Integration of models of drug-induced liver injury for risk assessment"*
Trans-QST and MIP-DILI, Sison-Young Rowena, University of Liverpool
- 34- *"Isocyanide Chemistry (IMCR): Promising Technology For Future Drug Discovery And Development"*
ELF, Pravin Patil, University Of Groningen
- 35- *"Developing human cellular phenotypic assays for pain"*
StemBANCC, Chintawar Satyan, University of Oxford
- 36- *"Transcriptomic analysis of the immune response to the rVSV-ZEBOV Ebola vaccine"*
VSV-EBOVAC, VSV-EBOPLUS, Santoro Francesco, University of Siena
- 37- *"Non-Canonical Hedgehog Signaling Is a Positive Regulator of the WNT Pathway and Is Required for the Survival of Colon Cancer Stem Cells"*
OncoTrack , Regan Joseph, Charité - Universitätsmedizin Berlin
- 38- *"A validated genetics-led system 'Pi' enables drug target discovery for immune traits"*
ULTRA-DD, Fang Hai, University Of Oxford
- 39- *"Immunobridging approach to assess clinical benefit as the basis for licensure of the monovalent Ebola vaccine"*
EBOVAC 1 and 2, Bockstal Viki, Janssen Vaccines & Prevention
- 40- *"A Bordetella pertussis human challenge model induces immunising colonization in absence of symptoms"*
PERISCOPE, de Graaf Hans, University of Southampton
- 41- *"Translational Safety Assessment in Pharma"*
eTRANSAFE, Ruud Bueters, Janssen



- 42- *"In vitro antimicrobial activity of tobramycin, colistin, aztreonam and the new antibiotic POL7080 against cystic fibrosis Pseudomonas aeruginosa growing in biofilms"*
iABC, Díez-Aguilar María, Hospital Universitario Ramón y Cajal-IRyCIS
- 43- *"Comparative assessment of seed extraction methods relevant for the study of Alzheimer disease"*
IMPRIND, Delay Charlotte, Janssen Pharmaceuticals
- 44- *"Frequencies of cerebrospinal fluid ATN biomarker profiles and their association with memory function in persons without dementia"*
EMIF-AD, Jansen Olin, Maastricht University

From concept to trial


- 45- *"Developing predictive in silico models for liver toxicity endpoints from in vivo histopathology data"*
eTOX, Pinto Gil Kevin, University Pompeu Fabra
- 46- *"Prognostic factors and outcome of multiple myeloma patients enrolled in European clinical trials after a long-term follow-up. A pilot project by multiple myeloma community within HARMONY consortium"*
HARMONY, D'Agostino Mattia, University of Turin
- 47- *"Altering disease course before symptom onset: the European Prevention of Alzheimer's Dementia (EPAD) project (WP4)"*
EPAD, Gheorghe Delia, University of Oxford
- 48- *"COMBACTE LAB-Net, a European laboratory network for clinical trials on anti-infectives to combat bacterial resistance"*
COMBACTE-NET, Kostyanev Tomislav, University of Antwerp
- 49- *"Tools to collect data on detection and prevalence of carbapenem-resistant Gram-negative bacteria among European laboratories part of the COMBACTE Laboratory network (LAB-Net)"*
COMBACTE-CARE and COMBACTE-NET, Kostyanev Tomislav, University of Antwerp
- 50- *"Exploring MMN processing in Autism Spectrum Disorder during the odd-ball task: evidence from the EU-AIMS LEAP cohort"*
EU-AIMS, Ahmad Jumana, King's College London
- 51- *"Novel peptide vaccines against Rift valley fever virus"*
ZAPI, Gutjahr Benjamin, Friedrich-Loeffler-Institut FLI
- 52- *"Identifying priority outcomes and understanding meaningful delay in disease progression for Alzheimer's Disease across the spectrum"*
ROADMAP, Ly Amanda, University of Edinburgh
- 53- *"Developmental changes in resting state power spectrum and functional connectivity in autism spectrum disorder"*
EU-AIMS, Garces Pilar, Roche
- 54- *"Implementing a Phase II Ebola Vaccine Trial (EBOVAC2) in Burkina Faso"*
EBOVAC2, Houreratou Barry, Centre MURAZ



- 55- *"A systematic review of guidelines for rigour in the design, conduct and analysis of biomedical experiments involving laboratory animals"*
EQIPD, Vollert Jan, Imperial College London
- 56- *"A Highly Productive Semi-Automated High Throughput Purification Process"*
ELF, Levy Laura Mariana, Taros
- 57- *"The Design and Synthesis of Innovative 3D Rich Scaffolds for Screening Libraries"*
ELF, Hristeva Stanimira, Taros
- 58- *"Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination: an observational cohort study"*
EBOVAC & EBOPLUS, Francesco Santoro, Universita' degli Studi di Siena

New clinical and regulatory paradigms

- 59- *"What is responsible antibiotic use? Towards a global definition"*
DRIVE-AB, Monnier Annelie, Radboud University Medical Center & Hasselt University
- 60- *"The added value of quantitative amyloid PET in determining Alzheimer's Disease (AD) dementia risk: the AMYPAD Prognostic and Natural History Study"*
AMYPAD, Lopes Alves Isadora, VU Medical Center Amsterdam
- 61- *"Towards an adaptive mindset"*
ADAPT SMART, Rohou Solange, Astrazeneca
- 62- *"Regulatory and HTA considerations for disease-modifying drugs in Alzheimer's disease"*
ROADMAP, O'Rourke Diana, National Institute for Health and Care Excellence (NICE)
- 63- *"Time-to-event case-control designs: An efficacious tool for cohort studies on nosocomial infections when resources are limited"*
COMBACTE, Feifel Jan, Ulm University
- 64- *"European Prevention of Alzheimer's Dementia (EPAD) Registry for a longitudinal cohort and Alzheimer prevention trials"*
EPAD, Vermunt Lisa, VU University Medical Center
- 65- *"Prioritisation and Intelligent Assessment of the Environmental Risks of Pharmaceuticals"*
iPiE, Wilkinson John, University of York
- 66- *"Alignment of European regulatory and health technology assessments: a review of licensed products for Alzheimer's Disease"*
ROADMAP, Dekker Marieke, Medicines Evaluation Board (MEB-CBG)
- 67- *"IMI-PROTECT and benefit risk assessment"*
PROTECT, Waddingham Edward, Imperial College London
- 68- *"Managing false-positive Ebola test results in the post-outbreak era: Experiences in the EBOVAC vaccine trial in rural Sierra Leone"*
EBOVAC, Baiden Frank, London School of Hygiene and Tropical Medicine



Patient engagement along the value chain

- 69- *“Characterising and appraising patient preference exploration and elicitation methods”*
PREFER, WhichelloChiara, Erasmus University Rotterdam
- 70- *“Prospective data collection on burden of RSV infection in Europe – paving the way for RSV vaccines and therapeutics”*
RESCUE, Wildenbeest Joanne G, Wilhelmina Children's Hospital, University Medical Center Utrecht
- 71- *“Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes”*
PARADIGM, Pakarinen Chi, the Synergist
- 72- *“Lessons learned in the recruitment of adolescents and children to the EBOVAC-Salone clinical trial in Sierra Leone”*
EBOVAC1, Thomas Mooney, the London School of Hygiene & Tropical Medicine
- 73- *“Bridging the gap between intention and action - Lessons learned from INNODIA’s Patient Advisory Committee”*
INNODIA, Soderberg Jeannette, JDRF

